STRUCTURED ABSTRACT
INTRODUCTION We investigated the link between habitual caffeine intake with memory deficits and CSF AD biomarkers in Mild cognitive impairment (MCI) and Alzheimer’s Disease (AD) patients.
METHODS MCI (N=147) and AD (N=116) patients of the BALTAZAR longitudinal cohort reported their caffeine intake using a dedicated survey and were followed-up for 3 years. Associations of caffeine consumption with cognition, MMSE decline and CSF biomarkers (Tau, pTau181, Aβ1-42, Aβ1-40) were analyzed using logistic and ANCOVA models.
RESULTS Adjusted on APOEε4, age, sex, education level and tobacco, lower caffeine consumption was associated with higher risk to be amnestic (OR: 2.49 [95%CI: 1.13 to 5.46]; p=0.023) and lower CSF Aβ1-42 (p=0.047), Aβ1-42/ Aβ1-40 (p=0.040) and Aβ1-42/pTau (p=0.020) in the whole cohort and a faster MMSE decline in amnestic MCI (p=0.024).
DISCUSSION Data supports the beneficial effect of caffeine consumption to memory decline and CSF amyloid markers in MCI and AD patients.
Competing Interest Statement
David Blum DB is a (non-appointed) member of the scientific advisory board of Marvel Biosciences Corp developing an A2AR antagonist but has no conflict of interest regarding the present work. Olivier Hanon received personal payment from Bayer, Servier, AstraZeneca, Boston Scientific, Vifor, BMS, Boehringer-Ingelheim, and Pfizer for lectures and/or consulting services. Jean Sebastien Vidal received payment from Bayer for lectures made to non-profit medical association. Sylvain Lehmann received for his institution support from the following: H2020 MARIE SKŁODOWSKA-CURIE MIRIADE Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis, ANR Flash Covid: ProteoCOVID: Clinical proteomic characterization of the SARS-CoV-2 Spike protein to optimize its detection and the development of serological assays, ANR Silk_road: The Stable Isotope Labeling Kinetics (SILK) road to investigate human protein turnover in blood and cerebrospinal fluid, EUROMET EMPIR NeuroMet2 project: Metrology and Innovation for early diagnosis and accurate stratification of patients with neurodegenerative diseases. During the past 36 months, he had a patent issued for Procede de preparation d un echantillon peptidique Brevet INPI n◦1905247 du 20/05/2019 du CHU DE MONTPELLIER, UNIVERSITE DE MONTPELLIER and SPOT TO LAB. He received personal payment for participating on the Roche Diagnostic board on CSF biomarkers. Stephanie Bombois, Bernadette Allinquant, Christiane Baret-Rose, Jean-Marc Treluyer, Hendy Abdoul, Patrick Gele, Christine Delmaire, Jean-Francois Mangin, and Evelyne Galbrun have no conflicts of interest. Frederic Blanc received honoraria from Roche and Biogen for presentations. He received payment to his institution as the national coordinator for the clinical trial DELPHIA for patients with dementia with Lewy bodies (Eisai). He received payment to his institution as the national coordinator for the clinical trial GRADUATE for patients with Alzheimer s disease. Luc Buee received support for the present manuscript from LabEx DISTALZ. He received grants or contracts from the French National Research Agency (ANR) Fondation pour la Recherche Medicale (FRM). In the past 36 months, he had a patent on anti-tau therapy issued. Jacques Touchon received payment or honoraria as chairman of CTAD. He received contracts from Regenlife and consulting fees from Regenlife. He is Chairman of JT Conseil society. Jacques Hugon received grants or contracts from Protekt therapeutics, consulting fees from Protekt therapeutics. He is principal investigator of RECAGE project European Union H20/20 programme and he is member of the scientific board of Fondation Philippe Chatrier, Paris, France. Bruno Vellas received grants or contracts from Biogen, Roche, and Lilly; consulting fees from Roche, Lily, Biogen, and Cerellis; and is part of WHO s ICOPE program (unpaid position). AthanBase Benetos is the president of the European Geriatric Medicine Society (unpaid position). He received support for attending meetings and/or travel from Fukuda company, for the Congress of the European Society of Hypertension, and received royalties or licenses from Cambridge University Editions. Gilles Berrut received a grant from Boehringer Ingelheim and consulting fees from Boehringer Ingelheim, Smart macadam Institut, bien vieillir Korian. Elena Paillaud has no conflicts of interest. David Wallon, Giovanni Castelnovo, Lisette Volpe-Gillot, Marc Paccalin, Philippe Robert, and Vincent Camus have no conflicts of interest. Olivier Godefroy received support to his institution for attending meetings and/or travel from BRISTOL-MYERS SQUIBB, ROCHE SAS, BIOGEN FRANCE SAS. Joel Belmin received consulting fees from Pfizer and honoraria from Novartis Pharma. Pierre Vandel is the president of the Societe Francophone de Psychogeriatrie et Psychiatrie de la Personne Agee (SF3PA) and received consulting fees from Eisai. Jean-Luc Novella, Emmanuelle Duron, Anne-Sophie Rigaud, Susanna Schraen-Maschke, Alain Duhamel, Nassima Ramdane, Lucie Vaudran, Caroline Dussart, Bernard Sablonniere and Audrey Gabelle have no conflicts of interest.
Clinical Protocols
https://classic.clinicaltrials.gov/ct2/show/NCT01315639
Funding Statement
The BALTAZAR study is supported by two grants from the French ministry of Health (Programme Hospitalier de Recherche Clinique, PHRC): PHRC2009/01-04 and PHRC-13-0404 and by the Foundation Plan Alzheimer. DB is supported by ANR JANUS (ANR-21-CE14-0053) and PHRC-I CAFCA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is ancillary to BALTAZAR (Biomarker of AmyLoid pepTide and AlZheimer s diseAse Risk), a multicenter (23 memory centers) prospective cohort study (ClinicalTrials.gov Identifier #NCT01315639) including participants with mild cognitive impairments (MCI) and Alzheimer s Disease (AD) at baseline from September 2010 to April 2015 and with an ongoing 3-year follow-up. All participants or their legal guardians gave written informed consent. The study was approved by the Paris Ethics Committee (CPP Ile de France IV Saint Louis Hospital).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
